1 min read
Add as a preferred source on Google

Ideaya Plans IDE849 Cohort for About 90 Patients With Neuroendocrine Cancer

The planned single-arm extension would enroll previously treated patients with gastroenteropancreatic neuroendocrine carcinoma in an ongoing Phase 1/2 study.

An unmarked study vial rests beside an empty treatment chair / TokenPost.ai
An unmarked study vial rests beside an empty treatment chair / TokenPost.ai

Ideaya Biosciences plans to begin a single-arm extension cohort of about 90 previously treated patients in its ongoing Phase 1/2 trial of IDE849 for gastroenteropancreatic neuroendocrine carcinoma.

The cohort is part of Ideaya’s registrational strategy for IDE849 in neuroendocrine carcinomas.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…